POPULARITY
Categories
PATREON: https://www.patreon.com/JulianDorey (***TIMESTAMPS in description below) ~ Baland Jalal is a Danish neuroscientist at Harvard University's Department of Psychology, whose work spans clinical neuroscience, cultural psychology, and the biology of altered state of consciousness. Originally from Denmark and of Kurdish-Iraqi descent, he is best known for his research on sleep paralysis. BALAND's LINKS: IG: https://www.instagram.com/balandjalal/# YT: https://www.youtube.com/channel/UCumyt6mGLaVO4_N1LkAoXdA WEBSITE: https://balandjalal.com/ FOLLOW JULIAN DOREY INSTAGRAM (Podcast): https://www.instagram.com/juliandoreypodcast/ INSTAGRAM (Personal): https://www.instagram.com/julianddorey/ X: https://twitter.com/julianddorey JULIAN YT CHANNELS - SUBSCRIBE to Julian Dorey Clips YT: https://www.youtube.com/@juliandoreyclips - SUBSCRIBE to Julian Dorey Daily YT: https://www.youtube.com/@JulianDoreyDaily - SUBSCRIBE to Best of JDP: https://www.youtube.com/@bestofJDP ****TIMESTAMPS**** 0:00 - Intro 01:46 – Baland's Classy Look & Upbringing 12:34 – Nations Are Just Stories 20:54 – Egypt Studies & Early Discoveries 30:50 – Brain Growth & Neuroplasticity 42:24 – Curing Depression with TMS 53:48 – The Power of REM Sleep 01:03:51 – Neuroscience of Empathy & OCD 01:19:39 – Academia, Peer Review, & Frustrations 01:29:10 – Why Dreams Feel So Real 01:38:21 – The Science Behind Dream Recall 01:47:35 – Time Distortion in Dreams 01:57:52 – Dreams as Emotional Therapy, Ghost Receptor 02:06:43 – Science Meets Spirituality 02:14:61 – The Mystery of the Hatman 02:26:10 – Science & Religion Intertwined 02:29:63 – Epigenetics & Generational Trauma 02:51:33 – Free Will & The Brain 03:09:63 – Intellect vs Emotion Systems CREDITS: - Host, Editor & Producer: Julian Dorey - COO, Producer & Editor: Alessi Allaman - https://www.youtube.com/@UCyLKzv5fKxGmVQg3cMJJzyQ - In-Studio Producer: Joey Deef - https://www.instagram.com/joeydeef/ Julian Dorey Podcast Episode 349 - Baland Jalal Music by Artlist.io Learn more about your ad choices. Visit podcastchoices.com/adchoices
The guys in Dissona chatted with us about not falling into the Progmetal trap, integrating world music into the sonic landscape, and their newest release, "Receptor." Learn more about your ad choices. Visit megaphone.fm/adchoices
BUFFALO, NY – October 20, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on October 16, 2025, titled “Widespread folate receptor expression in pediatric and adolescent solid tumors – opportunity for intraoperative visualization with the novel fluorescent agent pafolacianine.” In this study, led by first author Ashley C. Dodd from Ann & Robert H. Lurie Children's Hospital and corresponding author Timothy B. Lautz from the same institution and Northwestern University Feinberg School of Medicine, researchers discovered that folate receptor beta (FRβ) is widely expressed in various pediatric and adolescent solid tumors. This finding highlights FRβ as a promising target for improving the accuracy of tumor surgery using a fluorescent imaging agent known as pafolacianine. Pediatric cancers are often challenging to remove completely during surgery, particularly when tumors spread or form small metastases. Fluorescence-guided surgery is a method that helps surgeons better identify tumors during operations using special imaging dyes. However, commonly used dyes such as indocyanine green are not tumor-specific and rely on general features of blood vessel permeability, limiting their precision. In this study, researchers investigated the potential of pafolacianine, a next-generation dye that targets folate receptors, for pediatric use. Folate receptors are proteins commonly found on the surface of cancer cells. Pafolacianine is already FDA-approved for adults with ovarian and lung cancers due to its ability to bind these receptors and highlight tumors during surgery. The research team analyzed tissue samples from 13 young patients diagnosed with various cancers, including Wilms tumor, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, Ewing sarcoma, and neuroblastoma. The results showed that FRα was predominantly absent, whereas FRβ was present in 100% of the tumor samples. Notably, FRβ appeared both on the tumor cells and in the surrounding tumor microenvironment but showed little to no expression in normal tissue, making it an excellent candidate for targeted imaging. “In this study, we performed immunohistochemistry staining on slides obtained from a range of pediatric patients with solid tumors.” This consistent expression of FRβ in pediatric tumors is a significant and novel finding. Earlier studies primarily linked FRβ to immune cells called tumor-associated macrophages. This study reveals that FRβ is also expressed directly on tumor tissue, which could help surgeons better distinguish cancer from healthy tissue during procedures. Based on these results, the team has launched a clinical trial to evaluate pafolacianine in children undergoing surgery for metastatic lung tumors. If successful, this method could make pediatric cancer surgery safer and more effective. Overall, this study suggests that targeting FRβ with pafolacianine could serve as a tumor-agnostic imaging strategy, applicable across a wide range of pediatric solid tumors. This represents a potential advancement in real-time surgical imaging and a step forward in pediatric cancer care. DOI - https://doi.org/10.18632/oncotarget.28772 Correspondence to - Timothy B. Lautz - TLautz@luriechildrens.org Abstract video - https://www.youtube.com/watch?v=0its0QkOcwM Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Hey everyone,Fresh out the reactor this week, we've got brand new tunes Stonx ,Ichor, Kaizen Flow, Delayrz, Skorpion, Dropset, Receptor & Engage, SIREN, and Esym - serious heat front to back.Then we enter the Demo Room with fresh cuts from Meph & Karpa, Burr Oak, Direct Shift, Human Made, Zombie Cats & Nemean, Aye Rights, and another one from Esym closing things out in style.Check out the track list below and let's dive in!Stonx - Check The Beatcygnusmusic.link/er9bervTRACKLIST AND MORE INFO: www.stonxmusic.co.uk/stonxcast-ep161
We present the seventeenth episode of Eatbrain Radio Season 2, your guide to the dark side of drum and bass! Grimey, dutty and disgusting all the way! Hosted by @5ha5h label// facebook.com/Eatbra1n twitter.com/eatbrain_now instagram.com/eatbrain eatbrain.net Tracklist // 1. Burr Oak – No One Is Innocent (Audio Remix) [Eatbrain] 2. Bad Legs – The Exorcist (MV Remix) [Gutting Audio] 3. Burr Oak – Somewhere We Belong (Prolix Remix) [Eatbrain] 4. Zombie Cats & Nemean – Hulk [Creatured] 5. Sindicate & O&P – Loaded Gun (Karpa & Raido Remix) [Abducted LTD] 6. Burr Oak – Supreme Entity (Ed Rush Remix) [Eatbrain] 7. Mandidextrous & Matt Scratch – The Underneath [Neuroheadz] 8. Cliques – Scorpion (Hologram Remix) [Cliques Collective Audio] 9. Screamarts – Unruhe [Eatbrain] 10. Misanthrop – Deadlock (Emperor VIP) [Neosignal Recordings DUB] 11. Human Made – Take It Down [Paperfunk Recordings] 12. Meph & Combright – Time [Darkshire Sound] 13. Kaizen Flow – Insanity [Hanzom Music] 14. SIREN – Reset The System [Blackout Music NL] 15. Venshü – The Darkside [BrainRave Music] 16. Project Zeus – Gunk [Arrival Archetype] 17. Receptor & Engage – Surgeon [Evolution Chamber] 18. Psynchro – Test Me [Neuropunk Records] 19. Acaled – Take The Hell [High Resistance]
Nicotine isn't just addictive—it might be one of the most misunderstood nootropics in modern medicine. In this masterclass, you'll learn how controlled, low-dose nicotine may enhance brain performance, boost neuroplasticity, improve mitochondrial function, and potentially extend lifespan. Host Dave Asprey breaks down the surprising science behind this controversial compound, separating fact from fear—and exposing the real risks that nobody talks about. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR You'll discover how nicotine affects neurotransmitters, why it may help with ADHD and focus, and how it compares to other cognitive enhancers like caffeine, nootropics, and even smart drugs. Dave explores how nicotine can be used to hack metabolism, enhance sleep optimization, and support fasting or ketosis protocols—if used properly. He also reveals the forms of nicotine that are safest (spoiler: it's not vapes or cigarettes), how nicotine works at the receptor level, and what the science says about long-term health effects. This episode blends functional medicine, brain optimization, and biohacking into one powerful, myth-busting breakdown. You'll Learn: • How nicotine affects mitochondria, neurotransmitters, and dopamine signaling • Why nicotine may boost neuroplasticity, memory, and attention span • How low-dose nicotine compares to caffeine, modafinil, and other nootropics • The safest delivery forms (and the ones to avoid) • Whether nicotine supports or hinders longevity and cognitive resilience • How it can be stacked with supplements, fasting, or ketosis • What functional medicine says about chronic use, addiction, and withdrawal This is essential listening for anyone serious about biohacking, human performance, and longevity, and for those who want to understand how functional biology and mitochondrial science are redefining recovery, energy, and aging. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Nicotine microdosing, Nicotinic acetylcholine receptors, Dopamine and motivation, Cognitive enhancement, Alzheimer's prevention, Neuroinflammation, Mitochondrial function, TNF-alpha reduction, Vagus nerve activation, Longevity biohacking, Nicotine vs smoking, Nootropics, Attention and vigilance, Ketosis and metabolism, Functional medicine, Nicotine patches and gum, Addiction and tolerance, Receptor desensitization, Withdrawal protocols, Deep work performance Thank you to our sponsors! -TRU KAVA | Go to https://trukava.com/ and use code DAVE10 for 10% off. -HeartMath | Go to https://www.heartmath.com/dave to save 15% off. -Leela Quantum Tech | Check out all HEAL360 products and research and get 10% off at https://leelaq.com/DAVE. -Calroy | Head to https://calroy.com/dave for an exclusive discount. Resources: • Business of Biohacking | Register to attend October 20-23 in Austin, TX https://businessofbiohacking.com/ • Danger Coffee: https://dangercoffee.com/discount/dave15 • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Introduction 1:27 — History & Background of Nicotine 4:34 — How Nicotine Works 15:12 — Benefits & Research 16:43 — Risks & Who Should Avoid It 21:39 — Delivery Methods & Dosing 26:30 — Conclusion & Next Steps See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode, we review the high-yield topic of Selective Estrogen Receptor Modulators (SERMs)  from the Reproductive section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Hey everyone,Fresh out of the reactor this week we've got big new heaters from Stonx & Sindicate ft. Sodie, Audio & AKOV, KROT, Current Value, Dezpot & Modefunk, Smooth, Donny & Katharsys Remix LP, Subminderz & JIROBASS, and System Wide.In Demo's Wips & Promos we've got fresh cuts from Kaizen Flow & Stonx, Zigi SC & Phenom & Discharge, Burr Oak, Direct Shift, TRCD & Kryptomedic, plus Receptor & Engage.Check out the track list below and let's dive in!Disciples Of Distortion Vol4cygnusmusic.link/ddjeo14TRACKLIST AND MORE INFO: www.stonxmusic.co.uk/stonxcast-ep160
Today, we're speaking to Dr Sophie McGrath, Consultant Medical Oncologist based at the Royal Marsden NHS Foundation Trust and at Kingston Hospital in London.Title of paper: Management of menopausal symptoms following treatment for hormone receptor positive breast cancerAvailable at: https://doi.org/10.3399/BJGP.2025.0264This transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.Speaker A00:00:00.800 - 00:01:11.660Hello and welcome to BJJP Interviews. My name is Nada Khan and I'm one of the associate editors of the bjgp. Thanks for joining us today to listen to this podcast.In today's episode, we're speaking to Dr. Sophie McGrath, who is a consultant medical oncologist based at the Royal Morrison NHS Trust and at Kingston Hospital in London.We're here to talk about the recent analysis article that she and her colleagues have published here in the BJDP titled Management of Menopausal Symptoms Following Treatment for Hormone Receptor Positive Breast Cancer.And just to point out that these colleagues included not just medical oncologists, but also GPs and patients, which I think has really shaped this article and is one of the reasons why we wanted to highlight it here in the podcast. So, hi Sophie, thanks for meeting me to talk about this article, which I think touches on a really important topic in practice.But talk us through some of the initial side effects that you discuss in the introduction here. Just in terms of hormone positive breast cancer, what kind of symptoms do women experience generally as a result of endocrine therapy?Speaker B00:01:12.220 - 00:02:32.900So, yeah, thanks very much for asking. And it's a bit of a broad answer that I would give.I mean, I've focused on, or we have focused on three main symptoms within the article which relate to hot flushes or vasomotor symptoms, also to joint stiffness and pain and swelling, arthralgia, and also to vulvovaginal symptoms, otherwise known as genitourinary syndrome of menopause.But I think what we've tried to include within the article as well is a table that certainly acknowledges that there are unfortunately many other symptoms that women can get as a result of these medications, essentially mimicking menopausal side effects.And of course, you know, these might be symptoms that women having already gone through the menopause may have suffered or experienced at some point already.But actually for a population of premenopausal women, these will be symptoms that they haven't had any experience of yet and can often be quite intense and develop quite suddenly. Whereas often our post menopausal women have had some sort of lead up to this, they've had some experience.Speaker A00:02:34.710 - 00:02:44.710And you work as a medical oncologist. But just talk me through your own experience of working with women who are going through the sort of sudden menopause as you describe as well.Speaker B00:02:45.350 - 00:05:50.240So obviously the focus of the article here is on menopausal side effects in general from the treatments that we use. And we've talked a lot about using our endocrine treatments such as tamoxifen, letrozole.But actually many of our women also experience menopausal type side effect secondary to the chemotherapies we give them. So I think, you know, there's sort of two groups you often have, particularly premenopausal women who stop their periods whilst on chemotherapy.That may happen several weeks into their chemotherapy treatment and it can be quite sudden.You know, they're already dealing with the numerous side...
Hear from our experts on identifying opportunities for nsMRA use in treating HF and integrating nsMRAs into current HF treatment algorithms. Credit available for this activity expires: 9/3/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002874?ecd=bdc_podcast_libsyn_mscpedu
Triple-negative breast cancer is negative for both estrogen and progesterone receptors. So, it's hormone receptor-negative. People diagnosed with this type of breast cancer aren't offered hormonal therapy to reduce the risk of recurrence (the cancer coming back) because it's thought that they wouldn't be effective. Dr. Lisa Newman and colleagues published research that found that among people diagnosed with early-stage triple-negative breast cancer, nearly 33% of the recurrences or second primary breast cancers were hormone receptor-positive. This means the hormone receptor status had changed when the cancer came back or when there was a new cancer. The results raise this question: Should people with triple-negative disease be offered hormonal therapy to reduce the risk of recurrence? Listen to the episode to hear Dr. Newman explain: how she decided to investigate this issue why the results surprised her what the results mean for someone who's been diagnosed with triple-negative breast cancer with a high risk of recurrence
The first growth factors identified and studied during the early 1970s were Epidermal Growth Factor (EGF) and Nerve Growth Factor (NGF). It was soon demonstrated that EGF and NGF mediate their cellular and physiological effects by binding to specific cell membrane receptors: the EGF receptor (EGFR) and the NGF receptor (NGFR), respectively. The mechanisms of activation and signaling of these receptors were compared to those of insulin and IGF1, which bind and activate the Insulin Receptor (IR) and IGF1 Receptor (IGF1R). These comparisons gained further significance with the discovery that EGFR, NGFR, IR, IGF1R, and many other membrane receptors belong to the receptor tyrosine kinase (RTK) family of cell signaling molecules. Early insights into the activation and signaling mechanisms of EGFR revealed that ligand binding to its extracellular domain induces and stabilizes the formation of EGFR dimers. This dimerization plays a critical role in activating the receptor's intrinsic tyrosine kinase activity. Through an intermolecular process, this activation leads to the autophosphorylation of multiple tyrosine residues in the C-terminal tail of EGFR. The cytoplasmic domain of EGFR serves not only as an enzyme that phosphorylates various substrates but also as a scaffold that recruits and regulates multiple signaling proteins through complex formation. While different ligands induce RTK dimerization and activation through variations on a shared theme, this paradigm is universal among all RTKs and is similarly observed in the activation of other surface receptors. Further important discoveries regarding the mode of action of EGFR and other RTKs made during the 1970s and 1980s include the following: Signaling Modules: Molecules containing SH2, SH3, and other small protein modules were found to play key roles in mediating cellular activities downstream of RTKs and many other signaling molecules. Ligand-Dependent Endocytosis: Ligand binding to the extracellular domain of RTKs stimulates receptor-mediated endocytosis and intracellular trafficking ,which are essential for proper signal transduction. Oncogenic Mutations: A variety of gain-of-function oncogenic mutations were identified in EGFR and other RTKs. These mutations were shown to be critical drivers of many human cancers. These early discoveries, along with others made during the 1980s, laid the conceptual groundwork for the development of targeted therapies. They paved the way for the discovery and clinical application of more than 50 targeted small-molecule cancer drugs and therapeutic antibodies, which have significantly improved patient outcomes in oncology.
Interview with Tyson S. Barrett, PhD, and George M. Eid, MD, authors of Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. Hosted by Jamie Coleman, MD. Related Content: Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists
Interview with Tyson S. Barrett, PhD, and George M. Eid, MD, authors of Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. Hosted by Jamie Coleman, MD. Related Content: Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists
En este episodio, repasamos las primeras cinco posiciones del listado histórico de los receptores puertorriqueños en las Grandes Ligas. El análisis forma parte de la serie "Reyes de la Receptoría". Escucha el interesante diálogo del experimentado periodista deportivo Antolín Maldonado Ríos junto al subeditor de Deportes El Nuevo Día, José 'Kike' Bartolomei.
In this episode, we review the high-yield topic of IL-12 Receptor Deficiency from the Immunology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas review available efficacy and safety data guiding the optimal integration of oral SERDs into clinical practice. CME information and select publications here.
Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics: Introduction: ER-Positive Metastatic Breast Cancer — Bringing Research Data into Practice (0:00) Key Issues from the General Medical Oncologists (GMO) Survey (3:43) Faculty Cases and GMO Questions (44:43) CME information and select publications
Commentary by Dr. Jian'an Wang.
In episode 55 of Going anti-Viral, Dr Darcy Wooten joins host Dr Michael Saag to discuss navigating HIV care with glucagon-like peptide-1 (GLP-1) receptor agonists. Dr Wooten is a Professor of Medicine in the Division of Infectious Diseases at Washington University in St. Louis. Her clinical interests are HIV primary care, HIV prevention, sexually transmitted infections, and general infectious diseases. Dr Wooten is also a national leader in medical education. Dr Wooten provides an overview of GLP-1 receptor agonists including their history of use for the treatment of diabetes and more recent use for treatment of weight loss. Dr Saag and Dr Wooten discuss the challenges that patients have in getting insurance coverage for GLP-1 receptor agonists and review the 2 most common drugs that are used as treatment, tirzepatide and semaglutide. They discuss the patient experience with the injectable medication and review the possibility of oral versions of the medications in the future. Finally, Dr Saag and Dr Wooten discuss the long-term management of GLP-1 receptor agonists as a part of overall primary care for patients with HIV.0:00 – Introduction1:11 – Overview of GLP-1 receptor agonists3:46 – How GLP-1 receptor agonists became used for weight management and patient eligibility criteria6:14 – Challenges of insurance coverage for GLP-1 receptor agonists8:32 – Differences between theGLP-1 receptor agonists tirzepatide and semaglutide and other benefits of the medications beyond weight loss12:04 – Patient experience with the injectable formulations and possible adverse effects of use14:36 – Long-term use of GLP-1 receptor agonists and possibility of oral versions of these drugs17:36 – Managing GLP-1 receptor agonists as a part of primary care for patients with HIV including treatment of some substance use disorders20:22 – Predictions for future management of GLP-1 receptor agonists and Dr Wooten's hope for more research into incorporating lifestyle modifications into patient care __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...
Join here for expert analysis of the latest clinical trial data in HR-positive MBC and discussion of the clinical implications of these study results. Credit available for this activity expires: 8/18/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002835?ecd=bdc_podcast_libsyn_mscpedu
Deportes El Nuevo Día presenta una nueva serie de reportajes, titulada "Reyes de la Receptoría", para dar a conocer el trabajo y el desempeño de los receptores boricuas más sobresalientes en la historia de las Grandes Ligas. Conoce de qué se trata junto a nuestro editor de deportes, Carlos Rosa Rosa y el destacado periodista deportivo, Hiram Torraca.
Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.
Asesinan a periodista en Puebla Guerrero pide declaratoria de desastre en 8 municipios Demócratas ayudan a bloquear ley para destituir a Trump
In this week's episode, we'll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identification of an eight-protein risk signature as well as a novel single protein biomarker, soluble oncostatin M receptor, for risk stratification in AML.Featured Articles:Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiacMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pretransplant ConditioningBlood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes
Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49) PI3K Inhibition as First-Line Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (38:24) Clinical Utility of AKT and PI3K Inhibitors in Progressive HR-Positive mBC (1:01:44) Current and Future Role of Oral Selective Estrogen Receptor Degraders in HR-Positive mBC (1:24:38) NCPD information and select publications
Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein. NCPD information and select publications here.
Discutimos el futuro de los receptores Rome Odunze en Bears, Jaxon Smith-Njigba en Seahawks y Ladd McConkey en Chargers. =============
BUFFALO, NY - June 4, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 20, 2025, titled “Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells." In this study, authors Shan Lu and Zhongyun Dong from the University of Cincinnati College of Medicine investigated how interfering with a protein interaction could reduce prostate cancer growth. Their study based on prostate cancer cells shows that blocking the link between PCNA, a protein important for DNA repair, and the androgen receptor (AR), which drives prostate cancer growth, can slow down cancer cell multiplication. This discovery could lead to a new treatment for patients with advanced prostate cancer, particularly those no longer responding to hormone therapy. Prostate cancer is one of the most common cancers in men. Many patients eventually become resistant to hormone treatment. In this advanced stage, called castration-resistant prostate cancer (CRPC), tumors continue to grow by using either the full-length androgen receptor (AR-FL) or altered versions called AR variants (AR-Vs). This study shows that the interaction between AR and PCNA helps both AR-FL and AR-Vs remain active, supporting cancer cell survival and growth. The researchers identified a new region in the AR that binds to PCNA. They developed a small peptide, R9-AR-PIP, to mimic this region and block the AR-PCNA connection. They found that this peptide reduced AR's ability to bind DNA and lowered the levels of key genes involved in cancer cell growth. Importantly, the peptide was effective against both types of AR, including the variant forms that are especially challenging in CRPC. “We identified a second PIP-box (PIP-box592) in the DNA binding domain of AR and found that dihydrotestosterone enhances the binding of full-length AR (AR-FL) but not a constitutively active variant (AR-V7) to PCNA.” They also tested a small molecule, PCNA-I1S, which interferes with PCNA's ability to move to the cell nucleus and interact with AR. This molecule showed similar effects as the peptide, reducing AR activity and stopping cancer cell growth. Together, these findings suggest that targeting PCNA/AR interactions could be a promising strategy to fight CRPC, especially in patients with limited treatment options. One key result was that both the peptide and the small molecule reduced the levels of cyclin A2, a protein that helps cells divide and is often overexpressed in CRPC. Since this protein is linked to patients' poor outcomes, its reduction could be especially beneficial. This study improves our understanding of how prostate cancer continues to grow even after hormone treatments fail. By blocking a crucial helper of the androgen receptor, researchers have uncovered a new way to potentially slow or stop the disease. Further studies in animal models are needed, but this approach could lead to more effective treatments for men with advanced prostate cancer. DOI - https://doi.org/10.18632/oncotarget.28722 Correspondence to - Zhongyun Dong - dongzu@ucmail.uc.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28722 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCNA, androgen receptor, PCNA inhibitors, AR splicing variants, CRPC To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Dr. Centor discusses the effectiveness and safety of glucagon-like peptide-1 receptor agonists for weight loss in the absence of diabetes with Ms. Areesha Moiz.
In part two of this two-part series, Dr. Stacey Clardy and Dr. Elia Sechi discuss how to approach the management of patients in clinic when there is concern for a possible false positive on the radioimmunoprecipitation assay for the acetylcholine receptor antibody. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213498
In part one of this two-part series, Dr. Stacey Clardy and Dr. Elia Sechi discuss the clinical scenarios where the commonly used assay for myasthenia gravis is most likely to produce false positive results in patients who do not actually have myasthenia gravis. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213498
Dr. Stacey Clardy talks with Dr. Elia Sechi about the importance of understanding lab test results, the performance characteristics of assays, and the real-world implications of false positives in myasthenia gravis testing. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
Encuentra el video completo de este episodio en nuestro canal de YouTube “Piloto Football”
Hey everyone,Fresh out the reactor this week we've got bangers from Transforma, Receptor x Skrimor, TNTKLZ, MEL, Absu_NTQL, Confusion, Saint Rider & more.In Demos, WIPs, and Promos, we're checking out upcoming heaters from Current Value, Magnetude, Skrimor, Mizo & more.It's a bumper episode this week since we missed one last week — get locked in, big love from Ollie! Check out the track list below and let's dive in!Blinded Theory - Pass / Vyugahttps://cygnusmusic.link/knalmayDon't forget you can catch us LIVE recording Stonxcast on Twitch every Friday at 7pm (UK)TRACKLIST AND MORE INFO: www.stonxmusic.co.uk/stonxcast-ep138
Packers eligió a receptor en primera ronda por primera vez desde 2022. ¿Por qué rompieron tradición en el NFL Draft 2025?=============
Featuring an interview with Dr Adam M Brufsky, including the following topics: Case: A woman in her early 50s with ER-positive, HER2-low de novo metastatic breast cancer (0:00) Case: A woman in her late 70s with ER-positive, HER2-low metastatic breast cancer after 5 years of an adjuvant aromatase inhibitor (6:52) Clinical Investigator Survey Results (10:05) CME information and select publications
Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics: Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00) Comparing safety profiles of CDK4/6 inhibitors (9:49) Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06) Real-world evidence with CDK4/6 inhibitors (27:31) CME information and select publications
Hey everyone,Fresh out the reactor this week we've got bangers from Blinded Theory, Screamarts X Enta, 2Whales, Aye Rights & more.In Demos, WIPs, and Promos, we're checking out heaters from the likes of XAETIS, Receptor x Skrimor, Hologram, and Hackwaves & Pezutek.No end mix from our host Ollie this week as he's heading down to London for the Blender 2 Year Anniversary, playing a B2B with XAETIS — big love, see you next week!Blinded Theory - Pass / Vyugacygnusmusic.link/knalmayDon't forget you can catch us LIVE recording Stonxcast on Twitch every Friday at 7pm (UK)TRACKLIST AND MORE INFO: www.stonxmusic.co.uk/stonxcast-ep137
Aaron Rodgers habló sobre su salida de Jets, sus planes de offseason y su posible futuro con Pittsburgh. ¿Debe Steelers pensar en un plan B?=============
We present the seventh episode of Eatbrain Radio Season 2, your guide to the dark side of drum and bass! Grimey, dutty and disgusting all the way! Hosted by @5ha5h label// facebook.com/Eatbra1n twitter.com/eatbrain_now instagram.com/eatbrain eatbrain.net Tracklist // 1. Zigi SC – Recoil [Darkshire Sound] 2. Transforma & Gifta – The Way [Phase Records DNB] 3. Hologram – Crossfire [Eatbrain] 4. Forbidden Society – Kiro [Neksus Sound] 5. BAD SYNTAX – Wildfire (Diode Remix) [Abducted LTD] 6. Screamarts & Enta – Hellhound [Eatbrain] 7. Emperor – Death Tax [Overview Music] 8. Notequal – Echoes [Darkshire Sound, Free Download] 9. Receptor & Skrimor – Red Shift [Evolution Chamber] 10. Ed Rush & Optical – Chubrub (Buunshin Remix) [Patreon Dub] 11. Audio – Flip Mode (Prolix Remix) [Blackout Music] 12. Rift – Sun Skin [C4C Limited] 13. CiDiaH – Gate String [Neuroheadz] 14. Blinded Theory – Vyuga [Stonx Music] 15. PRDK – STARWALKIN [Patreon Dub] 16. Ntechnique & Hellkat – Buran [High Resistance] 17. Rieger – Confession [Paperfunk Recordings] 18. AKOV – Fake Blood [Self Release]
Hey everyone,This week, we've got fresh heaters from Manta, Xylym, Nemean, and Xaetis. Plus, we're diving into some epicDemos, WIPs, and Promos featuring Mythic Image, DIODE, Transforma & Paperclip, and the collab from Receptor x Skrimor.Ollie's back to guide you through this week's heavy selection.JIROBASS - Feral Seekers / The Blackwallcygnusmusic.link/w5plrmqDon't forget you can catch us LIVE recording Stonxcast on Twitch every Friday at 7pm (UK)TRACKLIST AND MORE INFO: www.stonxmusic.co.uk/stonxcast-ep134
A paralyzed man is able to move a robotic arm using only his thoughts with the help of AI and how the brain cannabinoid receptor is linked to stress. Plus, on This Day in History, we take a look at the Gold Standard Act. Paralyzed Man Moved a Robotic Arm Using Only His Thoughts Thanks to AI. It Kept Working for Months | ZME Science Brain Receptors For Cannabis Could Be Why Some People Are More Resilient : ScienceAlert Brain Cannabinoid Receptor Linked With Stress Resilience in Mice Astocyte endocannabinoid receptor and BBB linked with stress resilience | GEN Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood–brain barrier alterations | Nature Neuroscience What Is the Gold Standard? History and Collapse | Investopedia Contact the show - coolstuffcommute@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices
